Carcinoma, Non-Small-Cell Lung
Showing NaN - NaN of 46
NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +6 more
-
Tampa, Florida
- +112 more
Jan 30, 2023
NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +2 more
-
Tuscaloosa, Alabama
- +260 more
Dec 16, 2022
NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)
Recruiting
- Non-Small Cell Lung Cancer
- +13 more
- furmonertinib 240 mg
- +2 more
-
Yuma, Arizona
- +37 more
Dec 14, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab + SoC chemotherapy
- Placebo + SoC chemotherapy
-
Birmingham, Alabama
- +147 more
Aug 1, 2022
NSCLC Trial in Canton, Houston (FWD1509 MsOH)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- FWD1509 MsOH
-
Canton, Ohio
- +1 more
Jul 20, 2022
KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +9 more
- JDQ443
- +2 more
-
Atlanta, Georgia
- +31 more
Jul 7, 2022
NSCLC Trial in Worldwide (FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- FKB238 (bevacizumab)
- +3 more
-
Fountain Valley, California
- +146 more
Feb 25, 2022
NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- nab-paclitaxel IV
- +2 more
-
San Francisco, California
- +33 more
Jan 24, 2022
NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin)
Completed
- Carcinoma, Non-Small-Cell Lung
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- +3 more
-
Chandler, Arizona
- +239 more
Aug 26, 2021
NSCLC, Mesothelioma Trial in Canada, United States (LBH589)
Completed
- Carcinoma, Non-Small-Cell Lung
- Mesothelioma
-
Fayetteville, Arkansas
- +4 more
Dec 16, 2020
NSCLC Trial in Worldwide (Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Tislelizumab
- +2 more
-
Los Angeles, California
- +163 more
Jun 26, 2020
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (PF-05082566, rituximab)
Completed
- Lymphoma, Non-Hodgkin
- +6 more
-
Duarte, California
- +41 more
Mar 4, 2020
NSCLC, NSCLC Trial in Spain, United States (CC-223, erlotinib, CC-223, oral azacitidine)
Completed
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- CC-223, erlotinib
- CC-223, oral azacitidine
-
Los Angeles, California
- +8 more
Nov 7, 2019
NSCLC, NSCLC, NSCLC Trial in United States (Erlotinib (tarceva), Placebo)
Completed
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Erlotinib (tarceva)
- Placebo
-
Birmingham, Alabama
- +64 more
Sep 4, 2019
NSCLC, Carcinoma, Renal Cell, Breast Tumors Trial in United States (SGN-2FF, pembrolizumab)
Terminated
- Carcinoma, Non-Small-Cell Lung
- +7 more
-
Birmingham, Alabama
- +10 more
Jul 17, 2019
NSCLC Trial in United States (JNJ-64041757 (Cohort 1A and 1B), JNJ-64041757 (Cohort 2A and 2B))
Terminated
- Carcinoma, Non-Small-Cell Lung
- JNJ-64041757 (Cohort 1A and 1B)
- JNJ-64041757 (Cohort 2A and 2B)
-
Duarte, California
- +8 more
Nov 21, 2018